Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amicus Therapeutics, a biopharmaceutical company, has appointed Sol Barer to its board of directors.
Subscribe to our email newsletter
Dr Barer currently serves as chairman and CEO of Celgene. Dr Barer has received a PhD in organic chemistry from Rutgers University.
Separately, Amicus announced that Gregory Weinhoff has chosen to resign from the board of directors, effective January 7, 2009.
John Crowley, president and CEO of Amicus Therapeutics, said: “We look forward to Dr Barer’s leadership and guidance as Amicus continues along the path of development and commercialization for new, oral treatments for a range of human genetic diseases. We welcome him to our board.”